Investors Unfazed by Risks Associated With Bayer Drug
372604
The news that one of Bayer's over-the-counter painkillers may increase the risk of heart attacks and strokes barely fazed shareholders.
175709
Investors care more about the drugmaker's future than its Q4 results.
576936
Progress Software produces results in a tough market, but investors really don't care.
362559
Drug investors may be wishing they could pop two pills and feel better in the morning. The latest headache hit last week when Pfizer joined the rash of drug companies announcing problems with their products.
10668
Bayer AG may have known its withdrawn cholesterol-lowering drug Baycol caused a high rate of a serious muscle condition more than a year before it added a warning to its label, according to a prominent medical journal.
610181
Stock market investors are infamous for their laser focus on immediate results when they put a price on risk and potential reward every day. Unless, of course, they're investing in biotech stocks.
434277
The market might overlook the drug maker's promising programs.
404301
Mylan Laboratories Inc., the largest US maker of generic drugs, cautioned investors Friday that Thursday&#39;s jump in share price was likely driven by investor Carl Icahn&#39;s clearance to buy a large amount of company stock and fails to reflect &quot;negative ...
622596
Bayer (NYSE: BAY) is the latest company to find itself in hot water over a drug recall. But as the company gears up to burnish its image, the improvement in its financial performance promises
293928
Investors in Germany's Bayer will get one share in chemicals and polymers spin-off Lanxess for every 10 Bayer shares held, a German newspaper said, valuing Lanxess at nearly 1.6 billion euros ($1.97 billion). ...
202222
Stocks were little changed on Friday,  recovering after a sharp early drop on news from Pfizer Inc.  PFE.N that patients in a study showed an increased risk of  heart attacks after taking its popular Celebrex drug.
90408
Stock exchanges' stratospheric valuations may not reflect reality.
695798
Yet another delay from the FDA leaves investors hanging.
496302
Pfizer Inc.&#39;s bid to head off a Celebrex recall may get a boost from new government data showing the painkiller didn&#39;t raise heart risks in a study, while Aleve, which is sold by Bayer AG, did, investors said.
65084
NEW YORK, Feb. 26 -- Shares of United Therapeutics traded heavily Monday as the market reacted to scientific data affecting the Silver Spring drugmaker's lead product, Remodulin.
758167
Investors should be awake to Lunesta's potential pitfalls.
131381
Uncertainty is spreading like a cancer in the pharmaceutical investing world, and that&#39;s bad news for the segment&#39;s kingpin, Pfizer (NYSE: PFE).